206 related articles for article (PubMed ID: 33222406)
1. Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Ooki A; Morita S; Tsuji A; Iwamoto S; Hara H; Tanioka H; Satake H; Kataoka M; Kotaka M; Kagawa Y; Nakamura M; Shingai T; Ishikawa M; Miyake Y; Suto T; Hashiguchi Y; Yabuno T; Ando M; Sakamoto J; Yamaguchi K
Cancer Med; 2020 Dec; 9(24):9419-9430. PubMed ID: 33222406
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Ooki A; Morita S; Iwamoto S; Hara H; Tanioka H; Satake H; Kataoka M; Kotaka M; Kagawa Y; Nakamura M; Shingai T; Ishikawa M; Miyake Y; Suto T; Hashiguchi Y; Yabuno T; Sakamoto J; Tsuji A; Ando M; Yamaguchi K
Cancer Med; 2020 Mar; 9(5):1779-1789. PubMed ID: 31962002
[TBL] [Abstract][Full Text] [Related]
3. A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial.
Iwamoto S; Ooki A; Morita S; Hara H; Tanioka H; Satake H; Kataoka M; Kotaka M; Kagawa Y; Nakamura M; Shingai T; Ishikawa M; Miyake Y; Sudo T; Hashiguchi Y; Yabuno T; Sakamoto J; Tsuji A; Ando M; Yamaguchi K
Cancer Med; 2018 Sep; 7(9):4217-4227. PubMed ID: 30051609
[TBL] [Abstract][Full Text] [Related]
4. Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial.
Ooki A; Morita S; Tsuji A; Iwamoto S; Hara H; Tanioka H; Satake H; Kataoka M; Kotaka M; Kagawa Y; Nakamura M; Shingai T; Ishikawa M; Miyake Y; Suto T; Hashiguchi Y; Yabuno T; Ando M; Sakamoto J; Yamaguchi K
BMC Cancer; 2022 Jun; 22(1):711. PubMed ID: 35765021
[TBL] [Abstract][Full Text] [Related]
5. Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy.
Yamaguchi K; Ando M; Ooki A; Beier F; Guenther S; von Hohnhorst P; Van Cutsem E
Clin Colorectal Cancer; 2017 Jun; 16(2):e29-e37. PubMed ID: 28081962
[TBL] [Abstract][Full Text] [Related]
6. Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study.
Rosati G; Pinto C; Di Fabio F; Chiara S; Lolli IR; Ruggeri EM; Ciuffreda L; Ferrara R; Antonuzzo L; Adua D; Racca P; Bilancia D; Benincasa E; Stroppolo ME; Di Costanzo F
J Geriatr Oncol; 2018 May; 9(3):243-248. PubMed ID: 29433905
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.
Raimondi A; Di Maio M; Morano F; Corallo S; Lonardi S; Antoniotti C; Rimassa L; Sartore-Bianchi A; Tampellini M; Ritorto G; Murialdo R; Clavarezza M; Zaniboni A; Adamo V; Tomasello G; Petrelli F; Antonuzzo L; Giordano M; Cinieri S; Longarini R; Bergamo F; Niger M; Antista M; Peverelli G; de Braud F; Di Bartolomeo M; Pietrantonio F
Eur J Cancer; 2020 Aug; 135():230-239. PubMed ID: 32623288
[TBL] [Abstract][Full Text] [Related]
8. A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial.
Ooki A; Ando M; Sakamoto J; Sato A; Fujii H; Yamaguchi K
Jpn J Clin Oncol; 2014 Apr; 44(4):383-7. PubMed ID: 24558128
[TBL] [Abstract][Full Text] [Related]
9. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients.
Mol L; Ottevanger PB; Koopman M; Punt CJ
Eur J Cancer; 2016 Oct; 66():138-43. PubMed ID: 27573427
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T; Emi Y; Oki E; Kobayashi K; Tsuji A; Shimokawa M; Tanaka T; Akagi Y; Ogata Y; Baba H; Yoshida K; Natsugoe S; Maehara Y;
Cancer Chemother Pharmacol; 2016 Sep; 78(3):585-93. PubMed ID: 27468920
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20.
Wells JC; Tu D; Siu LL; Shapiro JD; Jonker DJ; Karapetis C; Simes J; Liu G; Price TJ; Tebbutt NC; O'Callaghan CJ
Clin Colorectal Cancer; 2019 Mar; 18(1):e140-e149. PubMed ID: 30595557
[TBL] [Abstract][Full Text] [Related]
13. Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial.
Wang L; Liu Y; Yin X; Fang W; Xiong J; Zhao B; Zhang M; Zou Y; Qiu H; Yuan X
JAMA Netw Open; 2020 Jul; 3(7):e2011036. PubMed ID: 32687588
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes and health-related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: a prospective cohort study.
Marques RP; Heudtlass P; Pais HL; Quintela A; Martins AP
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1719-1728. PubMed ID: 31037398
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
Ciardiello F; Normanno N; Martinelli E; Troiani T; Pisconti S; Cardone C; Nappi A; Bordonaro AR; Rachiglio M; Lambiase M; Latiano TP; Modoni G; Cordio S; Giuliani F; Biglietto M; Montesarchio V; Barone C; Tonini G; Cinieri S; Febbraro A; Rizzi D; De Vita F; Orditura M; Colucci G; Maiello E;
Ann Oncol; 2016 Jun; 27(6):1055-1061. PubMed ID: 27002107
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting.
Depenni R; Cossu Rocca M; Ferrari D; Azzarello G; Baldessari C; Alù M; Nolé F; Codecà C; Boscolo G; Piccininni M; Cavalieri S; Bossi P
Eur J Cancer; 2019 Jul; 115():4-12. PubMed ID: 31082692
[TBL] [Abstract][Full Text] [Related]
18. Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer.
Rosati G; Addeo R; Aprile G; Avallone A; Bilancia D; Brugnatelli S; Buccafusca G; Carlomagno C; Cordio S; Delfanti S; Dell'Aquila E; Di Bisceglie M; Di Donato S; Di Stasi A; Germano D; Giuliani F; Granetto C; Latiano TP; Leo S; Tralongo P; Stroppolo ME; Venturini F; Bianco S
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1089-1096. PubMed ID: 31493178
[TBL] [Abstract][Full Text] [Related]
19. Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer.
Köstek O; Demircan NC; Gökyer A; Küçükarda A; Sunal BS; Hacıoğlu MB; Eslame H; Solak S; Yılmaz E; Uzunoğlu S; Tunçbilek N; Çiçin I; Erdoğan B
Clin Transl Oncol; 2019 Nov; 21(11):1510-1517. PubMed ID: 30924091
[TBL] [Abstract][Full Text] [Related]
20. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
